Re: Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-grade Non-muscle-invasive Bladder Cancer on Tumor Recurrence
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F19%3A10394232" target="_blank" >RIV/00064203:_____/19:10394232 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11130/19:10394232
Výsledek na webu
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=L8GBjeqz0T" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=L8GBjeqz0T</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.eururo.2018.10.035" target="_blank" >10.1016/j.eururo.2018.10.035</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Re: Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-grade Non-muscle-invasive Bladder Cancer on Tumor Recurrence
Popis výsledku v původním jazyce
The authors present results from a randomized double-blind multicenter trial evaluating the role of single immediate instillation (SI) of gemcitabine after transurethral resection (TURB) of presumed low-grade (LG) non-muscle-invasive bladder cancer (NMIBC). Overall, 406 patients were randomized to SI of 2 g of gemcitabine in 100 ml of saline or to 100 ml of saline alone within 3 h after TURB, and 383 completed the trial. After median follow-up of 4 yr, 35% of patients in the gemcitabine arm and 47% in the saline group experienced recurrence in an intention-to-treat (ITT) analysis (hazard ratio [HR] 0.66, 95% confidence interval [CI] 0.48-0.90; p < 0.001). In the prespecified target population with pathologically confirmed LG NMIBC, 34 of 102 patients receiving gemcitabine (34%) and 59 of 113 patients receiving saline (54%) had recurrences (HR 0.53, 95% CI 0.35-0.81; p = 0.001).
Název v anglickém jazyce
Re: Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-grade Non-muscle-invasive Bladder Cancer on Tumor Recurrence
Popis výsledku anglicky
The authors present results from a randomized double-blind multicenter trial evaluating the role of single immediate instillation (SI) of gemcitabine after transurethral resection (TURB) of presumed low-grade (LG) non-muscle-invasive bladder cancer (NMIBC). Overall, 406 patients were randomized to SI of 2 g of gemcitabine in 100 ml of saline or to 100 ml of saline alone within 3 h after TURB, and 383 completed the trial. After median follow-up of 4 yr, 35% of patients in the gemcitabine arm and 47% in the saline group experienced recurrence in an intention-to-treat (ITT) analysis (hazard ratio [HR] 0.66, 95% confidence interval [CI] 0.48-0.90; p < 0.001). In the prespecified target population with pathologically confirmed LG NMIBC, 34 of 102 patients receiving gemcitabine (34%) and 59 of 113 patients receiving saline (54%) had recurrences (HR 0.53, 95% CI 0.35-0.81; p = 0.001).
Klasifikace
Druh
O - Ostatní výsledky
CEP obor
—
OECD FORD obor
30217 - Urology and nephrology
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2019
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů